Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334602 | 0.87 | NPC1 (0.67) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL1037140 | 0.82 | PTGER4 (0.52) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL10328650 | 0.82 | RAB9A (0.50) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL10328621 | 0.82 | NPC1 (0.53) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL9356623 | 0.80 | RAB9A (0.52) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL17112794 | 0.80 | NPC1 (0.51) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL10328616 | 0.80 | RXRA (0.52) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL10328542 | 0.79 | MRGPRX4 (0.50) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL10328594 | 0.79 | MEN1 (0.50) | NPC1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL10328645 | 0.78 | LMNA (0.43) | NPC1CYP1A2CYP2C19RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2120923-B1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI SA (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008086949-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | PC, PCK1, PDK4 | NPC1 1500/4885CYP1A2 325/4885CYP2C19 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.